Chocolate manufacturer Barry Callebaut secured the positive opinion from EFSA.
Barry Callebaut (Zurich, Switzerland) just secured a positive opinion for a health claim for cocoa flavanols and healthy blood flow. The health claim will be the first earned for cocoa in the European Union.
Raw cocoa beans are highly concentrated with flavanols. When derived from cocoa, these plant compounds have been linked to potential benefits for cognition and mood, cholesterol, blood pressure, and blood circulation.
EFSA (Parma, Italy) concluded that enough data is available to support a link between cocoa flavanol consumption and the maintenance of normal endothelium-dependent vasodilation. In fact, several studies suggest that consuming high amounts of cocoa flavanols can support healthy blood flow even in at-risk populations, such as smokers, overweight subjects, diabetics, and the elderly.
Efficacy, however, appears to rely on very high amounts of cocoa flavanols.
Because traditional chocolate manufacturing relies on high-heat processing which can destroy flavanols, companies like Barry Callebaut have focused their efforts on creating advanced processes that retain high amounts of flavanols in finished cocoa and chocolate ingredients. EFSA’s opinion is based on findings with Barry Callebaut’s ACTICOA process, which the company says preserves up to 80% of raw cocoa flavanols.
In order to obtain the claimed effect on healthy blood circulation, EFSA recommends daily consumption of 200 mg of cocoa flavanols (2.5 g of high-flavanol cocoa powder or 10 g of high-flavanol dark chocolate).
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.